Mucosal melanoma is a rare and aggressive subtype which, unlike cutaneous melanoma, shows limited response to immune checkpoint inhibition. Here, the authors report the safety and efficacy of neoadjuvant pembrolizumab (anti-PD-1) and lenvatinib (multi tyrosine kinase inhibition) in patients with resectable mucosal melanoma, along with exploratory biomarker analysis.